Jet Bio-Filtration(SH:688026) Zhong Guo Zheng Quan Bao·2026-02-04 20:29Core Viewpoint - Jiet Bio has evolved from a small workshop to a leading enterprise in the domestic biological laboratory consumables sector, focusing on core technology and long-term development to become a global leader in comprehensive solutions for biological laboratories [1][2]. Company Development - Founded in 2001, Jiet Bio specializes in the R&D, production, and sales of life science consumables related to cell culture and liquid handling [1]. - The company has undergone three key phases: foundational period (2001-2010), expansion period (2011-2019), and capitalization and high-quality development period (2020-present) [1]. - Jiet Bio aims to break the import monopoly and achieve domestic production of laboratory consumables, starting with core products like cell culture dishes and centrifuge tubes [1]. Capitalization and Growth - In 2020, Jiet Bio successfully listed on the Sci-Tech Innovation Board, becoming the first "domestic consumables stock," which accelerated its development through capital market leverage [2]. - The company has established a GMP-grade clean production base and transformed from a "single product supplier" to a "comprehensive solution provider" for biological laboratories, serving over 40 countries and regions [2]. Innovation and Technology - Jiet Bio has invested 500 million yuan in a smart manufacturing factory, marking a significant step towards intelligent manufacturing and global market positioning [2][3]. - The factory, designed according to Industry 4.0 standards, enhances production efficiency by over 60% and maintains a product qualification rate of over 99.8% [3]. Future Strategy - During the "14th Five-Year Plan" period, Jiet Bio's core strategy focuses on transitioning from a consumables leader to a comprehensive solution provider for biological laboratories, extending its supply chain upstream and downstream [4]. - The company plans to establish 2-3 regional headquarters or production bases overseas to enhance local production and service capabilities [4]. - Jiet Bio aims to maintain a research and development investment ratio of no less than 8% of revenue annually, with a focus on advanced technologies like 3D cell culture consumables and intelligent laboratory equipment [4]. Investor Returns - Jiet Bio is committed to returning value to investors through stable growth, reasonable dividends, and value enhancement, with a planned cash dividend ratio of no less than 30% of net profit over the next three years [5]. - The company has initiated a share buyback program, investing nearly 5 million yuan to repurchase 272,800 shares [5].